Busan Union Technology Holdings 'Share&Service' Receives Approval for Confirmatory Clinical Trial of Respiratory Rehabilitation Digital Therapeutic Device 'EasyBreed'

Clinical Trial Conducted for Patients with Chronic Obstructive Pulmonary Disease

Image showcasing the EasyBreed app developed by Share&Service.

[Asia Economy Yeongnam Reporting Headquarters Reporter Kim Yong-woo] Share & Service (CEO Choi Hee-eun), a subsidiary of Busan United Technology Holdings (CEO Seong Hee-yeop), has completed approval from the Ministry of Food and Drug Safety for the confirmatory clinical trial plan of the respiratory rehabilitation digital therapeutic device ‘EasyBreathe’.

Established in 2020, Share & Service is a faculty startup company from Inje University Haeundae Paik Hospital specializing in digital therapeutic devices for patients with chronic obstructive pulmonary disease (COPD).

The technology holding company announced on the 29th that it will enter the confirmatory clinical trial of the digital therapeutic device EasyBreathe in a consortium with Professor Lee Jae-ha of the Department of Pulmonology at Haeundae Paik Hospital, Professor Lee Jin-guk of Seoul St. Mary’s Hospital at the Catholic University, and Professor Kim Cheol’s team at Inje University Sanggye Paik Hospital.

Through this confirmatory clinical trial, they plan to verify the clinical efficacy and safety of the digital therapeutic device targeting patients with chronic obstructive pulmonary disease who require respiratory rehabilitation treatment, with the ultimate goal of obtaining product approval.

CEO Choi Hee-eun pointed out, “Chronic obstructive pulmonary disease ranks third among the leading causes of death worldwide, with an estimated 3.3 million patients in South Korea. Due to the lack of preventive management, acute exacerbations frequently recur, and it is practically difficult to receive respiratory rehabilitation treatment even after discharge.”

CEO Choi emphasized, “In a situation where the number of chronic pulmonary disease patients is increasing due to an aging society, air pollution and fine dust, and new infectious diseases, the development of the digital therapeutic device ‘EasyBreathe’ has made it possible to provide professional respiratory rehabilitation treatment and preventive management based on clinical prescriptions anytime and anywhere.”

A representative of Busan United Technology Holdings said, “This is the first time a startup in the non-capital region at the seed investment stage has entered a confirmatory clinical trial,” and added, “We will support startups in the Busan area to continue their sustainable development.”

This content was produced with the assistance of AI translation services.